Novavax prepares for COVID-flu vaccine combo amid research blitz - Sydney Morning Herald

The vaccine supplier is forecasting revenues of up to $US5 billion now that it’s selling doses to Australia and the world and expects to launch a new trial of its combined flu and coronavirus vaccine later this year.

The boss of COVID-19 maker Novavax says the company expects to launch a new trial of its combined flu and coronavirus vaccine later this year, while confirming the biotech expects revenues of up to $… [+1714 chars]

full article...